A Phase 4 interventional study of Bictegravir, emtricitabine, and tenofovir alafenamide in HIV -1 Infection, HIV (Human Immunodeficiency Virus) and HIV, sponsored by CAN Community Health. Recruiting at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by CAN Community Health · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment. These pauses in medication can happen for many reasons, such as side effects, challenges with getting to the clinic, personal circumstances, stigma, or difficulties with everyday life. When HIV treatment is stopped, the viral load can increase, which may affect a person's health and make it easier for HIV to be passed on to others. Restarting treatment quickly after an interruption is important for both personal and public health. However, it can be difficult for people who miss doses to get back on treatment right away. There are often several steps and medical appointments required before restarting, such as waiting for lab results or reviewing medical history, which can cause further delays. These additional steps can make it even harder for people to re-engage and may discourage them from returning to care.
The REINITIATE study is designed for people living with HIV who have not taken any antiretroviral medications for at least the last 12 weeks. The study will offer participants a way to restart their HIV therapy quickly, by beginning treatment with B/F/TAF on the same day that they return to care. B/F/TAF is a widely used, once-daily HIV regimen, and is recommended in national treatment guidelines.
Researchers want to find out if this rapid restart approach is safe and effective, and whether it helps people regain control of HIV and remain in care. The study will also examine how many participants are able to keep the virus at a low level (viral suppression), stay engaged in their HIV care, and tolerate the medication after rapidly restarting treatment. In addition, the study will include interviews with some participants, to gain a better understanding of why they stopped taking their medications and what supported their return to treatment. These insights could help healthcare teams develop better ways to support people living with HIV in the future.
This prospective, multicenter, open-label, single-arm, Phase 4, interventional study aims to evaluate rapid antiretroviral therapy (ART) restart with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in participants' routine clinical environments, facilitating data collection on treatment effectiveness and safety following same-day ART reinitiation amongst treatment-experienced people with HIV (PWH) who have had a treatment interruption of at least 12 weeks. This study will also characterize reasons for ART interruption and reinitiation.
B/F/TAF, a three-drug combination of bictegravir (B; a second-generation HIV-1 integrase strand transfer inhibitor [INSTI]), and emtricitabine (F) and tenofovir alafenamide (TAF), both nucleoside reverse transcriptase inhibitors (NRTIs), is a recommended initial ART regimen for most people with HIV in the United States. B/F/TAF is an oral, once-daily fixed-dose combination (FDC) that provides a potent and well-tolerated regimen for the treatment of HIV-1 infection in people, including those with some pre-existing resistance and subpopulations that are underrepresented in clinical trials, including Black, Hispanic, and Latine PWH, PWH ≥65 years old, and pregnant adults.
The rapid restart nature of this study involves the concurrent initiation of screening, baseline assessments, and administration of B/F/TAF on the same day. B/F/TAF is the only guideline-recommended single tablet regimen (STR) suitable for rapid restart, as it can be prescribed without prior knowledge of baseline laboratory parameters, including viral load, hepatitis B virus (HBV) status, or baseline genotypic resistance testing. This means the study treatment commences without baseline test results, provided the participant fulfills all eligibility criteria.
There will be two Cohorts of participants within this study: Cohort 1 will include viremic participants (defined by HIV-1 RNA ≥50 copies/mL) at baseline and Cohort 2 will include virologically suppressed participants (defined by HIV-1 RNA \<50 copies/mL) at baseline. The study will aim to recruit 125 participants into Cohort 1 while simultaneously recruiting into Cohort 2 (it is assumed approx. 15-75 participants). The ratio of participants in Cohort 1 and Cohort 2 will be monitored during enrollment. Adherence and drop-out rates will be closely monitored throughout the study to mitigate the risk of insufficient sample sizes to power the planned analyses. Each participant's total study participation duration will be up to 48 weeks for data collection. Participants will be followed prospectively for 48 weeks in Cohort 1 and for 24 weeks in Cohort 2. Optional, semi-structured interviews will be conducted for a subset of participants in Cohorts 1 and 2 via teleconference at week 4 and week 24 after baseline screening and treatment reinitiation. While sample size will be informed by theoretical saturation, \~30 participants (15 per Cohort) is estimated to be sufficient.
Achieving viral suppression (defined as HIV-1 RNA \<50 copies/mL) is the main goal of ART therapy for PWH who are viremic, and the primary objective of this study. It has been associated with improvements in CD4 cell counts, prevention of HIV drug resistance, AIDS- and non-AIDS-related events, and decreased transmission to sexual partners of PWH. Secondary outcomes include safety, resistance, persistence and adherence, and a range of patient-reported outcomes to understand patient experiences of ART.
3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's planned enrollment of 200 is above the median of 96 across 2,254 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →CAN Community Health is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants receive open-label B/F/TAF. Treatment duration is determined by baseline viral load: viremic participants (defined by HIV-1 RNA ≥50 copies/mL) at baseline will receive 48 weeks of B/F/TAF; virologically suppressed participants (defined by HIV-1 RNA \<50 copies/mL) at baseline will receive 24 weeks of B/F/TAF.
Drug: Bictegravir, emtricitabine, and tenofovir alafenamide
Drug pages: BictegravirStudies of BictegravirBictegravir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · EmtricitabineStudies of EmtricitabineEmtricitabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Tenofovir alafenamideStudies of Tenofovir alafenamideTenofovir alafenamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Oral, film-coated tablet containing 50 mg BIC, 200 mg FTC, and 25 mg TAF taken once daily with or without food administered for 24 or 48 weeks.
Also known as: B/F/TAF, BIKTARVY®
Percentage of participants in Cohort 1 with plasma HIV-1 RNA <50 copies/mL
Percentage of all participants who have plasma HIV-1 RNA Viral Load \<50 c/mL at W24 using FDA snapshot analysis, which defines a participant's virologic response status using only the viral load at the predefined timepoint within a certain window of time, along with study drug discontinuation
Time frame: Week 24
Percentage of participants in Cohort 2 with plasma HIV-1 RNA ≥50 copies/mL
Percentage of all participants who have plasma HIV-1 RNA Viral Load ≥50 c/mL at W24 using FDA snapshot analysis, which defines a participant's virologic response status using only the viral load at the predefined timepoint within a certain window of time, along with study drug discontinuation
Time frame: Week 24
Percentage of participants with plasma HIV-1 RNA <50 copies/mL
Percentage of participants with HIV-1 RNA \<50 copies/mL assessed at Weeks 12, 24, and 48, using FDA snapshot analysis and missing values excluded
Time frame: 48 weeks
Percentage of participants with plasma HIV-1 RNA <200 copies/mL
Percentage of participants with HIV-1 RNA \<200 copies/mL assessed at Weeks 12, 24, and 48, using FDA snapshot analysis and missing values excluded
Time frame: 48 weeks
Percentage of participants meeting protocol-defined virologic failure (PDVF) criteria in Cohort 1
Percentage of participants meeting PDVF criteria through Weeks 24 and 48. For Cohort 1, PDVF will be defined as Suboptimal Virologic Response, in which HIV-1 RNA ≥50 copies/mL and less than 1 log10 HIV-1 RNA reduction from Day 1 at the W12 visit, or Virologic Rebound, in which at any timepoint after achieving HIV-1 RNA \<50 copies/mL, a subsequent HIV-1 RNA measurement is noted to be ≥50 copies/mL, which is then confirmed at the following scheduled or unscheduled visit
Time frame: 48 weeks
Percentage of participants meeting PDVF criteria in Cohort 2
Percentage of participants meeting PDVF criteria through Weeks 24 and 48. For Cohort 2, PDVF will be defined as Confirmed Virologic Rebound, in which at any visit after Day 1, a rebound in HIV-1 RNA to ≥50 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit, or any participant with HIV-1 RNA ≥50 copies/mL at the last on-treatment study visit (including E/D, lost to follow-up, or study endpoints)
Time frame: 24 weeks
Absolute and change from baseline in log10 HIV-1 RNA viral load of participants
Absolute and change from baseline in log10 HIV-1 RNA viral load at Weeks 12, 24, and 48
Time frame: 48 weeks
Absolute and change from baseline CD4 T-cell count of participants
Absolute and change from baseline CD4 T-cell count at Weeks 12, 24, and 48. The CD4 T-cell count will be determined using the participant's blood sample. This test serves as a marker of immune system integrity and is used to evaluate immune suppression and disease progression, and monitor B/F/TAF efficacy
Time frame: 48 weeks
Percentage of participants discontinuing due to adverse events (AEs) or intolerability
Percentage of patients discontinuing study treatment due to AEs or other intolerability through Weeks 24 and 48
Time frame: 48 weeks
Percentage of participants experiencing treatment-emergent Grade 3-4 laboratory abnormalities
Incidence of new Grade 3-4 lab abnormalities through Weeks 24 and 48
Time frame: 48 weeks
Percentage of participants experiencing treatment-emergent Grade 3-4 drug-related adverse events
Incidence of Grade 3-4 adverse events considered drug-related through Weeks 24 and 48
Time frame: 48 weeks
Percentage of Participants experiencing Serious Adverse Events (SAEs)
Incidence of SAEs through Weeks 24 and 48. All SAEs will be collected from the date of the first dose of the study drug until the end of on-study treatment + 30 days
Time frame: 48 weeks
Baseline resistance to B/F/TAF
Proportion of participants with pre-existing genotypic or phenotypic resistance to any component of B/F/TAF at study entry
Time frame: 4 weeks
Treatment-emergent resistance in PDVF participants in Cohort 1
Proportion of participants with PDVF who develop treatment-emergent genotypic or phenotypic resistance to any component of B/F/TAF. For Cohort 1, PDVF will be defined as Suboptimal Virologic Response, in which HIV-1 RNA ≥50 copies/mL and less than 1 log10 HIV-1 RNA reduction from Day 1 at the W12 visit, or Virologic Rebound, in which at any timepoint after achieving HIV-1 RNA \<50 copies/mL, a subsequent HIV-1 RNA measurement is noted to be ≥50 copies/mL, which is then confirmed at the following scheduled or unscheduled visit
Time frame: 48 weeks
Treatment-emergent resistance in PDVF participants in Cohort 2
Proportion of participants with PDVF who develop treatment-emergent genotypic or phenotypic resistance to any component of B/F/TAF. For Cohort 2, PDVF will be defined as Confirmed Virologic Rebound, in which at any visit after Day 1, a rebound in HIV-1 RNA to ≥50 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit, or any participant with HIV-1 RNA ≥50 copies/mL at the last on-treatment study visit (including E/D, lost to follow-up, or study endpoints)
Time frame: 24 weeks
Total satisfaction score on the HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs)
Total score at Weeks 4, 24, and 48 on the HIVTSQs on a scale of 0 (very dissatisfied) to 6 (very satisfied)
Time frame: 48 weeks
Change from Week 4 on the Total HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) score
Change in total HIVTSQ satisfaction score from Week 4 to Weeks 24 and 48 on a scale of 0 (very dissatisfied) to 6 (very satisfied)
Time frame: 48 weeks
Total and change from baseline in the symptom distress score on the HIV-Symptom Index (HIV-SI)
Total score and change from baseline at Weeks 4, 24, and 48 on the HIV-SI on a scale of 0 ("I do not have this symptom") to 4 ("It bothers me a lot")
Time frame: 48 weeks
Health-related quality of life by EuroQol 5-Dimension 5-Level (EQ-5D-5L) total score and change from baseline
Total EQ-5D-5L score and change from baseline at Weeks 4, 24, and 48 with a scale ranging from 0 (the worst health you can imagine) to 100 (the best health you can imagine)
Time frame: Week 4
Reasons for prior ART discontinuation and current reinitiation
Participant-reported reasons for previous ART discontinuation and for reinitiation at study entry
Time frame: Baseline
Proportion of participants lost to follow-up
Participants with no study contact through Week 48
Time frame: Week 48
Proportion of participants on study drug with documented clinic visit
Participants taking study drug at Week 48 who have a clinic visit within 90 days after their post-treatment safety follow-up visit (Week 48 + 30 days)
Time frame: Week 48
Adherence to B/F/TAF by pill count or dried blood spot (DBS)
Adherence rate as measured by pill counts or DBS at scheduled and/or unscheduled visits through Week 48
Time frame: Week 48
Participant experiences returning to care after HIV treatment interruption
Semi-structured qualitative interviews will be conducted at Weeks 4 and 24 to investigate the experience of PWH who are returning to care after interrupting treatment, including barriers to initial retention in care and reasons for disengagement, motivators for re-engagement with care, as well as barriers to this process, perceptions about future risk of disengagement with care following re-engagement, and impact of restarting treatment on first visit with B/F/TAF
Time frame: Week 24
Plan to share: No — Individual participant data (IPD) from this study will not be made available to other researchers. This decision is based on considerations related to the vulnerability of the study population and the need to uphold the highest standards of data protection and confidentiality. Given that participants are living with HIV-1, which is a condition associated with significant social, legal, and personal sensitivities, sharing IPD could increase the risk of inadvertent disclosure of sensitive personal information. Ensuring the privacy and protection of identities and health data of participants is essential; therefore, we have decided not to make IPD available for other researchers' use.
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 64 non-industry phase 4 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 49. This study's planned 12 months is below that.
Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 22 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide
Acquired Immunodeficiency Syndrome →
CAN Community Health